Nanomedicine (Lond). 2014 Apr;9(4):435-49. doi: 10.2217/NNM.13.66.
To improve the immunological response against tumors, a vaccine based on nanoliposomes targeted to the Fcg-receptor was developed to enhance the immunogenicity of tumor-associated antigens (TAAs).
MATERIALS & METHODS: Using human dendritic cells in vitro, a fragment of the TAA NY-ESO-1 combined with a T-helper peptide from the tetanus toxoid encapsulated in nanoliposomes was evaluated. In addition, peptides Palm-IL-1 and MAP-IFN-g were coadministered as adjuvants to enhance the immunological response.
Coadministration of Palm-IL-1 or MAP-IFN-g peptide adjuvants and the hybrid NY-ESO-1-tetanus toxoid (soluble or encapsulated in nanoliposomes without targeting) increased immunogenicity. However, the most potent immunological response was obtained when the peptide adjuvants were encapsulated in liposomes targeted to human dendritic cells via the Fc receptor.
This targeted vaccine strategy is a promising tool to activate and deliver antigens to dendritic cells, thus improving immunotherapeutic response in situations in which the immune system is frequently compromised, as in advanced cancers.
为了提高针对肿瘤的免疫反应，开发了一种针对 Fcg 受体的载脂蛋白疫苗，以增强肿瘤相关抗原（TAA）的免疫原性。
在体外使用人树突状细胞，评估与破伤风类毒素 T 辅助肽结合的 TAA NY-ESO-1 片段，该片段被包裹在载脂蛋白纳米脂质体中。此外，还共同给予 Palm-IL-1 和 MAP-IFN-g 肽佐剂以增强免疫反应。
共给予 Palm-IL-1 或 MAP-IFN-g 肽佐剂和杂交 NY-ESO-1-破伤风类毒素（可溶或包裹在纳米脂质体中而不靶向）可提高免疫原性。然而，当肽佐剂通过 Fc 受体靶向人类树突状细胞被包裹在脂质体中时，可获得最强的免疫反应。
这种靶向疫苗策略是一种很有前途的工具，可以激活并向树突状细胞递呈抗原，从而改善免疫系统经常受损的情况下的免疫治疗反应，如晚期癌症。
